SM
BPMC

Stephen Mandel’s Blueprint Medicines BPMC Stock Holding History

Stephen Mandel’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,709,138
Closed -$263M – 39
2021
Q1 		$263M Hold
2,709,138
– – 0.96% 30
2020
Q4 		$304M Buy
+2,709,138
New +$285M 1.1% 32

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Stephen Mandel's BPMC Position: Q2 2021 in Review

Stephen Mandel sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 2,709,138 shares — an estimated $263M sold.

Stephen Mandel first reported a position in BPMC in Q4 2020 and held it in 2 quarters. The position peaked at $304M in Q4 2020. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

  • Stephen Mandel reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
  • Stephen Mandel sold 2,709,138 Blueprint Medicines shares in Q2 2021, an estimated $263M.
  • Stephen Mandel first reported a position in Blueprint Medicines in Q4 2020 and held it in 2 quarters.
  • Stephen Mandel's Blueprint Medicines position peaked at $304M in Q4 2020.
  • 281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on Lone Pine Capital's 13F filing for Q2 2021, filed 16 Aug 2021.